Navigation Links
ITN type 1 diabetes study identifies subset of patients with strong response to therapy
Date:8/15/2013

WA, Seattle (August 15, 2013) Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled "Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes" (AbATE), was conducted by the Immune Tolerance Network (ITN). The results are available online and will be published in the November issue of the journal Diabetes.

The AbATE study, led by Kevan Herold, MD (Yale University), tested teplizumab, which targets the CD3 receptor found on T cells, in patients with new-onset type 1 diabetes. CD3 is required for T-cell activation, which can lead to the destruction of insulin-producing beta cells. A previous ITN study with teplizumab showed that a single course of the drug slowed C-peptide decline in new-onset patients for a year, after which the effects waned. The aim of the AbATE study was to test whether C-peptide preservation could be prolonged by administering two courses of teplizumab, one year apart.

In this open-label, Phase II study, 77 new-onset patients (ages 8 to 30 years old) were randomized to receive either teplizumab or a control. Those in the treatment arm received the scheduled treatment consisting of two 14-day courses of teplizumab, one year apart. Both arms received intensive diabetes care from certified diabetes educators and were followed for two years. The primary endpoint compared C-peptide preservation between the two groups.

After two years, the teplizumab-treated group showed significantly greater preservation of C-peptide (75-percent higher responses compared to the control grou
'/>"/>

Contact: Philip Bernstein, Ph.D.
ITNCommunications@immunetolerance.org
240-235-6132
Immune Tolerance Network
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Diabetes Research Institute develops oxygen-generating biomaterial
2. New study shines light on barriers to diabetes care in NYC Bangladeshi community
3. Commonly used diabetes drug may help to prevent primary liver cancer
4. Approach to diabetes self-management too narrow, study suggests
5. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
6. From feast to famine: A metabolic switch that may help diabetes treatment
7. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
8. Jack Spratt diabetes gene identified
9. Diabetes drug makes brain cells grow
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Joslin researchers gain new understanding of diabetes and kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... tuna aggregate under floating objects, such as lengths of ... mammals. There is still no full explanation for this ... purse-seine fishery operators take advantage of the associated concentrations ... buoys which act as FADs. An enormous purse-seine net, ...
... found in green tea may be able to stave ... apnea (OSA), according to a new study published in ... Societys American Journal of Respiratory and Critical Care Medicine. ... administered through drinking water, on rats who were intermittently ...
... vast array of physical and biological systems across the ... humans, says a new analysis of information not previously ... things include earlier leafing of trees and plants over ... altitudes in the northern hemisphere; changes in bird migrations ...
Cached Biology News:Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 3Green tea compounds beat OSA-related brain deficits 2Warming climate is changing life on global scale, says new study 2
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early ... excellent customer service. Images such as the Fonz in a lab coat and Large ... to the humdrum spectroscopy field. , FireflySci is proud to be the only ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held companies ... three years through 2014. Being named to the Inc. 5000 list designates a company ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated Tad ...
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended June ... in Canadian dollars and presented under International Financial ... activities with respect to our Oral Amp B ... contract manufacturer," said Andrew Rae , President ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... Solution Enables Enhanced Productivity and Decreased Expenses, ... Inc., the global leader,in helping academic, healthcare ... procurement, today announced that BioMarin,Pharmaceutical Inc., a ... the SciQuest eprocurement platform to streamline and,enhance ...
... a white paper titled “Avanta AC™ Advanced ... Nanopowders” online. This white paper outlines the ... a nanometer scale, as well as the ... Advanced ceramic nanopowders are critical to a ...
... appeals to the Senate Judiciary Committee for a hearing regarding covert surveillance ... it were not for the fact that real people are being victimized ... ... Ohio (PRWEB) June 24, 2008 -- As the issue of torturing foreign ...
Cached Biology Technology:SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 2Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 3Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 4
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: